Study of the implications of the WTO TRIPS Agreement fotr the pharmaceutical industry in Thailand (The Centre for Health Economics, Faculty of Economics, Chulalongkorn University Bangkok - WHO Collaborating Centre for Health Economics - WHO/SEARO, 1999, 113 p.): 8. Suggestions for Further Study

Study of the implications of the WTO TRIPS Agreement fotr the pharmaceutical industry in Thailand (The Centre for Health Economics, Faculty of Economics, Chulalongkorn University Bangkok - WHO Collaborating Centre for Health Economics - WHO/SEARO, 1999, 113 p.)

		(introductory text...)
		Acknowledgements
		Executive Summary
		1. Introduction
		2. Overview of the Pharmaceutical Industry
		3. Health Care Facilities
		4. Drug Market Situation
		5. Effects of the TRIPS Agreement on the Domestic Pharmaceutical Industry
		6. Conclusion
		7. Recommendations: 11 Ps Strategies
		8. Suggestions for Further Study
		References

8. Suggestions for Further Study

This study attempted to analyse the implications of the TRIPS Agreement for the pharmaceutical industry in Thailand. However, with ongoing change in the structure of the economy, regulations, patent laws, and the environment, these continuing issues need to be addressed in further study. In order to understand the impact of the TRIPS Agreement, we need to use longitudinal data such as consumer and producer behaviour, health status of the Thai people, etc. In other words, to have a more suitable price control system, we should study price structure setting, especially after some drug items have passed their SMP's under the new 1999 Patent Act, as well as the impact of parallel import and its consequences, and the affect of the Patent Act on consumers' behaviour, the local pharmaceutical industry, and people's health status.